The rising incidence of various types of cancers, especially breast and prostate cancer, has created new opportunities for growth within the global companion diagnostic tests for oncology market. There is tremendous demand for improved technologies within the field of oncology, and advancements in companion diagnostics has supported the growth of this domain. Medical research has continually focused on finding antidotes to the development of fatal cancers or tumours in the human body. Several of these researchers have tasted success in their endeavours. However, there lie several unmet needs within the domain of oncology. Considering this fact, it is expected that the investments of the medical industry in companion diagnostic tests would increase.
Global Companion Diagnostic Tests in Oncology Market: Snapshot
The global companion diagnostic tests in oncology market is expected to register phenomenal pace owing to increasing adoption of new tests, and rising shift from blockbuster drugs to personalized medicines, and targeted therapies. Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer. Increasing focus on research and development by various pharmaceutical and biotechnology companies, along with medical device companies, and increasing funding and grants for cancer research by various government agencies have led to high adoption of companion diagnostic tests in oncology. According to the research report, the global companion diagnostic tests in oncology market is expected to be worth US$13.6 bn by the end of 2025 from US$3.5 bn in 2016. During the forecast period of 2017 and 2025, the global market is projected to rise at a CAGR of 16.8%.
EGFR Biomarker to Remain Popular Amongst Pharmaceutical Companies
Among the biomarker segment, the EGFR biomarker segment accounted for the largest share of the global companion diagnostic tests in oncology market in 2016. It is expected to register highest CAGR during the forecast period of 2017-2025, owing to major factors such as increasing incidence of lung cancer, and rising R&D in biomarker segment. The HER2 and KRAS biomarkers are expected to register high CAGR during the forecast period, due to increasing incidence of cancer, and rising adoption of biomarker by pharmaceutical companies and research institutes. Analysts expect that the EGFR biomarker segment will register a CAGR of 18.4% over the forecast period.
Among the cancer types segment, the breast cancer segment accounted for the largest share of the global companion diagnostic tests in oncology market in 2016. However lung cancer segment is expected to register highest CAGR during the forecast period of 2017-2025, owing to increasing incidence of lung cancer in developing countries. This shift is attributable to the increased smoking and rising biomarker research for the lung cancer treatment. According to statistics from the World Health Organization (WHO), in 2013, an estimated 1.9 million new cases of lung cancer were diagnosed, and the stats reveled that less developed regions including the emerging countries such as China, India, and other countries, had the highest incidence of lung cancer, owing to rising smoking habits and poor air quality in these countries.
North America to Remain Dominant with Higher Acceptance of Technologies
Geographically, the global companion diagnostic tests in oncology market is segmented into North America, the Middle East and Africa, Asia Pacific, Europe, and Latin America. Analysts expect that North America will continue to dominate the global market due to the higher acceptance of technology in the region. Furthermore, better rate of diagnoses in the region is also likely to favor the regional market’s growth. By the end of 2025, the regional market is projected to account for a share of 37.5% in the global market. On the other hand, Asia Pacific is also expected to offer lucrative opportunities due to high rate of unmet medical needs in the emerging economies of the region.
Major players having presence in the global companion diagnostic tests in oncology market include F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher Scientific, Inc., among others.
The global companion diagnostic tests in oncology market is segmented as follows:
By Detection Technique |
|
by Biomarker |
|
by Cancer Type |
|
by End Users |
|
by Geography |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Digital Companion Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1 Detection Technique Definition
4.1.2 Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1 Drivers
4.4.2 Restraints
4.4.3 Opportunity
4.5. Global Digital Companion Diagnostics Market Analysis and Forecasts, 2015–2025
4.5.1 Market Revenue Projections (US$ Mn)
4.6. Porter’s Five Force Analysis
4.7. Market Outlook
4.8. Future Trends: response-guided therapy, theranostic
4.9. FDA breakthrough therapies: For Companion Diagnostic Tests
4.10. Overview FDA approved in-vitro Companion Diagnostic Tests
4.11. Companion Diagnostics and regulatory requirements : region wise
4.12. Companion Diagnostic Tests - Intended Diagnostics Type - Market Players
4.13. Pipeline Overview: Major market players
5. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Detection Technique
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast By Detection Technique , 2015–2025
5.4.1 Protein Detection
5.4.1.1 Immunohistochemistry
5.4.2 DNA Detection
5.4.2.1 Polymerase Chain Reaction
5.4.2.2 Next Gen Sequencing
5.4.2.3 In-Situ Hybridization
5.4.3 Others
5.5. Market Attractiveness By Detection Technique
6. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Bio-markers
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Forecast By Bio-markers, 2015–2025
6.4.1. EGFR
6.4.2. KRAS
6.4.3. BRAF V600E
6.4.4. HER2
6.4.5. Others
6.5. Market Attractiveness By Bio-markers
7. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Cancer Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Value Forecast By Cancer Type , 2015–2025
7.4.1 Breast Cancer
7.4.2 Liver Cancer
7.4.3 Lung Cancer
7.4.4 Colorectal Cancer
7.4.5 Melanoma
7.4.6 Others
7.5. Market Attractiveness By Cancer Type
8. Global Digital Companion Diagnostics Market Analysis and Forecasts, By End User
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Value Forecast By End User , 2015–2025
8.4.1 Hospitals
8.4.2 Specialty Clinics
8.4.3 Diagnostic Labs
8.4.4 Others
8.5. Market Attractiveness By End User
9. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Policies and Regulations
9.3. Market Value Forecast By Region
9.3.1 North America
9.3.2 Europe
9.3.3 Asia Pacific
9.3.4 Latin America
9.3.5 Middle East and Africa
9.4. Market Attractiveness By Country/Region
10. North America Digital Companion Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1 Key Findings
10.1.2 Policies and Regulations
10.1.3 Key Trends
10.2. Market Value Forecast By Detection Technique, 2015–2025
10.2.1 Protein Detection
10.2.1.1 Immunohistochemistry
10.2.2 DNA Detection
10.2.2.1 Polymerase Chain Reaction
10.2.2.2 Next Gen Sequencing
10.2.2.3 In-Situ Hybridization
10.2.3 Others
10.3. Market Value Forecast By Bio-markers, 2015–2025
10.3.1 EGFR
10.3.2 KRAS
10.3.3 BRAF V600E
10.3.4 HER2
10.3.5 Others
10.4. Market Value Forecast By Cancer Type , 2015–2025
10.4.1 Breast Cancer
10.4.2 Liver Cancer
10.4.3 Lung Cancer
10.4.4 Colorectal Cancer
10.4.5 Melanoma
10.4.6 Others
10.5. Market Value Forecast By End User , 2015–2025
10.5.1 Hospitals
10.5.2 Specialty Clinics
10.5.3 Diagnostic Labs
10.5.4 Others
10.6. Market Value Forecast By Country , 2015–2025
10.6.1 U.S.
10.6.2 Canada
10.6. Market Attractiveness Analysis
10.6.1 By Detection Technique
10.6.2 By Bio-markers
10.6.3 By Cancer Type
10.6.4 By End User
10.6.5 By Country
11. Europe Digital Companion Diagnostics Market Analysis and Forecast 11.1. Introduction
11.1.1 Key Findings
11.1.2 Policies and Regulations
11.1.3 Key Trends
11.2. Market Value Forecast By Detection Technique , 2015–2025
11.2.1 Protein Detection
11.2.1.1 Immunohistochemistry
11.2.2 DNA Detection
11.2.2.1 Polymerase Chain Reaction
11.2.2.2 Next Gen Sequencing
11.2.2.3 In-Situ Hybridization
11.2.3. Others
11.3. Market Value Forecast By Bio-markers , 2015–2025
11.3.1 EGFR
11.3.2 KRAS
11.3.3 BRAF V600E
11.3.4 HER2
11.3.5 Others
11.4. Market Value Forecast By Cancer Type , 2015–2025
11.4.1 Breast Cancer
11.4.2 Liver Cancer
11.4.3 Lung Cancer
11.4.4 Colorectal Cancer
11.4.5 Melanoma
11.4.6 Others
11.5. Market Value Forecast By End User , 2015–2025
11.5.1 Hospitals
11.5.2 Specialty Clinics
11.5.3 Diagnostic Labs
11.5.4 Others
11.6. Market Value Forecast By Country , 2015–2025
11.6.1 U.K.
11.6.2 Germany
11.6.3 France
11.6.4 Italy
11.6.5 Spain
11.6.6 Russia
11.6.7 Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1 By Detection Technique
11.7.2 By Bio-markers
11.7.3 By Cancer Type
11.7.4 By End User
11.7.5 By Country
12. Asia Pacific Digital Companion Diagnostics Market Analysis and Forecast 12.1. Introduction
12.1.1 Key Findings
12.1.2 Policies and Regulations
12.1.3 Key Trends
12.2. Market Value Forecast By Detection Technique , 2015–2025
12.2.1 Protein Detection
12.2.1.1 Immunohistochemistry
12.2.2 DNA Detection
12.2.2.1 Polymerase Chain Reaction
12.2.2.2 Next Gen Sequencing
12.2.2.3 In-Situ Hybridization
12.2.3 Others
12.3. Market Value Forecast By Bio-markers , 2015–2025
12.3.1 EGFR
12.3.2 KRAS
12.3.3 BRAF V600E
12.3.4 HER2
12.3.5 Others
12.4. Market Value Forecast By Cancer Type , 2015–2025
12.4.1 Breast Cancer
12.4.2 Liver Cancer
12.4.3 Lung Cancer
12.4.4 Colorectal Cancer
12.4.5 Melanoma
12.4.6 Others
12.5. Market Value Forecast By End User , 2015–2025
12.5.1 Hospitals
12.5.2 Specialty Clinics
12.5.3 Diagnostic Labs
12.5.4 Others
12.6. Market Value Forecast By Country , 2015–2025
12.6.1 India
12.6.2 China
12.6.3 Japan
12.6.4 Australia & New Zealand
12.6.5 Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1 By Detection Technique
12.7.2 By Bio-markers
12.7.3 By Cancer Type
12.7.4 By End User
12.7.5 By Country
13. Latin America Digital Companion Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1 Key Findings
13.1.2 Policies and Regulations
13.1.4 Key Trends
13.2. Market Value Forecast By Detection Technique , 2015–2025
13.2.1 Protein Detection
13.2.1.1 Immunohistochemistry
13.2.2 DNA Detection
13.2.2.1 Polymerase Chain Reaction
13.2.2.2 Next Gen Sequencing
13.2.2.3 In-Situ Hybridization
13.2.3 Others
13.3. Market Value Forecast By Bio-markers , 2015–2025
13.3.1 EGFR
13.3.2 KRAS
13.3.3 BRAF V600E
13.3.4 HER2
13.3.5 Others
13.4. Market Value Forecast By Cancer Type , 2015–2025
13.4.1 Breast Cancer
13.4.2 Liver Cancer
13.4.3 Lung Cancer
13.4.4 Colorectal Cancer
13.4.5 Melanoma
13.4.6 Others
13.5. Market Value Forecast By End User , 2015–2025
13.5.1 Hospitals
13.5.2 Specialty Clinics
13.5.3 Diagnostic Labs
13.5.4. Others
13.6. Market Value Forecast By Country , 2015–2025
13.6.1 Brazil
13.6.2 Mexico
13.6.3 Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1 By Detection Technique
13.7.2 By Bio-markers
13.7.3 By Cancer Type
13.7.4 By End User
13.7.5 By Country
14. Middle East and Africa Digital Companion Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1 Key Findings
14.1.2 Policies and Regulations
14.1.4 Key Trends
14.2. Market Value Forecast By Detection Technique , 2015–2025
14.2.1 Protein Detection
14.2.1.1 Immunohistochemistry
14.2.2 DNA Detection
14.2.2.1 Polymerase Chain Reaction
14.2.2.2 Next Gen Sequencing
14.2.2.3 In-Situ Hybridization
14.2.3 Others
14.3. Market Value Forecast By Bio-markers , 2015–2025
14.3.1 EGFR
14.3.2 KRAS
14.3.3 BRAF V600E
14.3.4 HER2
14.3.5 Others
14.4. Market Value Forecast By Cancer Type , 2015–2025
14.4.1 Breast Cancer
14.4.2 Liver Cancer
14.4.3 Lung Cancer
14.4.4 Colorectal Cancer
14.4.5 Melanoma
14.4.6 Others
14.5. Market Value Forecast By End User , 2015–2025
14.5.1 Hospitals
14.5.2 Specialty Clinics
14.5.3 Diagnostic Labs
14.5.4 Others
14.6. Market Value Forecast By Country , 2015–2025
14.6.1 South Africa
14.6.2 GCC Countries
14.6.3 Rest of Middle East and Africa
14.7. Market Attractiveness Analysis
14.7.1 By Detection Technique
14.7.2 By Bio-markers
14.7.4 By Cancer Type
14.7.5 By End User
14.7.6 By Country
15. Competition Landscape
15.1 Market Player – Competition Matrix (By Tier and Size of companies)
15.2 Market Share Analysis By Company (2015)
15.3 Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1 Abbott
15.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.1.2 Financial Overview
15.3.1.3 Product Portfolio
15.3.1.4 SWOT Analysis
15.3.1.5 Strategic Overview
15.3.2 F. Hoffman LA Roche Ltd.
15.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.2.2 Financial Overview
15.3.2.3 Product Portfolio
15.3.2.4 SWOT Analysis
15.3.2.5 Strategic Overview
15.3.3 Genomic Health, Inc.
15.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.3.2 Financial Overview
15.3.3.3 Product Portfolio
15.3.3.4 SWOT Analysis
15.3.3.5 Strategic Overview
15.3.4 QIAGEN
15.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.4.2 Financial Overview
15.3.4.3 Product Portfolio
15.3.4.4 SWOT Analysis
15.3.4.5 Strategic Overview
15.3.5 Agilent Technologies, Inc.
15.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.5.2 Financial Overview
15.3.5.3 Product Portfolio
15.3.5.4 SWOT Analysis
15.3.5.5 Strategic Overview
15.3.6 AGENDIA NV
15.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.6.2 Financial Overview
15.3.6.3 Product Portfolio
15.3.6.4 SWOT Analysis
15.3.6.5 Strategic Overview
15.3.7 bioMerieux SA
15.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.7.2 Financial Overview
15.3.7.3 Product Portfolio
15.3.7.4 SWOT Analysis
15.3.7.5 Strategic Overview
15.3.8 Illumina, Inc.
15.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.8.2 Financial Overview
15.3.8.3 Product Portfolio
15.3.8.4 SWOT Analysis
15.3.8.5 Strategic Overview
15.3.9 Siemens Healthcare GmBH
15.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.9.2 Financial Overview
15.3.9.3 Product Portfolio
15.3.9.4 SWOT Analysis
15.3.9.5 Strategic Overview
15.3.10 Thermo Fisher Scientific, Inc.
15.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.10.2 Financial Overview
15.3.10.3 Product Portfolio
15.3.10.4 SWOT Analysis
15.3.10.5 Strategic Overview
15.3.11 BioGenex
15.3.11.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.11.2 Financial Overview
15.3.11.3 Product Portfolio
15.3.11.4 SWOT Analysis
15.3.11.5 Strategic Overview
List of Tables
Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 06: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 07: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 09: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 11: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 12: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 13: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 14: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 16: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 17: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 18: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 19: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 20: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 21: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 22: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 23: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique,
Table 24: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 25: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 26: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 27: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 28: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 29: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 30: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 31: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 32: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 33: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 34: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 35: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 36: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 37: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 38: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 39: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 40: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 41: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 42: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
List of Figures
Figure 01: Global Companion Diagnostic Tests in Oncology, Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type (2016)
Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker (2016)
Figure 04: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique (2016)
Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region (2016)
Figure 06: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user (2016)
Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 08: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 09: Global Protein Detection Technique in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 10: Global DNA Detection Technique in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 11: Global Other Detection Techniques in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 14: Global Companion Diagnostic Tests in Oncology Market, by EGFR Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 15: Global Companion Diagnostic Tests in Oncology Market, by KRAS Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 16: Global Companion Diagnostic Tests in Oncology Market, by BRAF V600E Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 17: Global Companion Diagnostic Tests in Oncology Market, by HER2 Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 18: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 19: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 20: Global Companion Diagnostic Tests in Oncology Market, by Breast Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 21: Global Companion Diagnostic Tests in Oncology Market, by Lung Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 22: Global Companion Diagnostic Tests in Oncology Market, by Liver Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 23: Global Companion Diagnostic Tests in Oncology Market, by Colorectal Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 24: Global Companion Diagnostic Tests in Oncology Market, by Melanoma Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 25: Global Companion Diagnostic Tests in Oncology Market, by Other Cancers, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 26: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 27: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 28: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Pharmaceutical & Biotechnology Companies, 2015–2025
Figure 29: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Medical Device Companies, 2015–2025
Figure 30: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Research Laboratories, 2015–2025
Figure 31: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Others, 2015–2025
Figure 32: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2017 and 2025
Figure 33: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Region, 2017–2025
Figure 34: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 35: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2017 and 2025
Figure 36: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 37: North America Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 38: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 39: North America Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 40: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 41: North America Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 42: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 43: North America Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 44: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 45: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 46: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025
Figure 47: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 48: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 49: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 50: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 51: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 52: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 53: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 54: Europe Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 55: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 56: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 57: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025
Figure 58: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 59: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 60: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 61: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 62: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 63: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 64: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 65: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 66: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 67: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 68: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025
Figure 69: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 70: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 71: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 72: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 73: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 74: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 75: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 76: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 77: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 78: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 79: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2017 and 2025
Figure 80: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2017–2025
Figure 81: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2017 and 2025
Figure 82: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2017–2025
Figure 83: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 84: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 85: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2017 and 2025
Figure 86: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2017–2025
Figure 87: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2017 and 2025
Figure 88: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2017–2025
Figure 89: Global Companion Diagnostic Tests in Oncology Market Share, by Company, 2016